NCT03238027: A Phase 1, Open-label, Dose Escalation Trial to Investigate SNDX-6352 in Patients With Solid Tumors

NCT03238027
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with untreated unstable central nervous system (CNS) metastases and/or carcinomatous meningitis- see trial for details; Patients previously treated with a CSF-1, CSF-1R, and/or IL-34-blocking agents and/or prior exposure to immune-mediated therapy including, but not limited to, other anti CTLA-4, anti-PD-1, anti-PD-L1/2 antibodies, excluding therapeutic anticancer vaccines;
https://ClinicalTrials.gov/show/NCT03238027

Comments are closed.

Up ↑